NCT00785759
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Amnestic Mild Cognitive Impairment, +8 more
- Locations
-
- GE Healthcare Oslo, Norway
Clinical trial condition
Neurocognitive Disorders
Explore clinical trials studying Neurocognitive Disorders. Study availability and eligibility vary by location and protocol.
7,727 public trials
1,421 recruiting studies
Neurocognitive Disorders trial results
NCT00099710
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Brain Diseases, +7 more
- Locations
-
- UCLA Medical Center Westwood, Los Angeles, California, United States
NCT00182988
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Brain Diseases, +7 more
- Locations
-
- Georgetown University Medical Center Washington D.C., District of Columbia, United States
NCT00931073
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Basal Ganglia Diseases, +17 more
- Locations
-
- Pfizer Investigational Site Kalamazoo, Michigan, United States
NCT00394017
- Conditions
- Brain Diseases, Central Nervous System Diseases, Dementia, +3 more
- Locations
-
- Research Unit of General Practice Copenhagen, Capital Province, Denmark
NCT00838877
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Brain Diseases, +7 more
- Locations
-
- Research Site Huddinge, Sweden
- Research Site Stockholm, Sweden
Completed
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
NCT00455000
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Brain Diseases, +7 more
- Locations
-
- Pfizer Investigational Site Heidelberg West, Victoria, Australia
- Pfizer Investigational Site Fremantle, Western Australia, Australia
- Pfizer Investigational Site Nedlands, Western Australia, Australia
- Pfizer Investigational Site London, Ontario, Canada
Completed
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
NCT00329082
- Conditions
- Alzheimer Disease, Alzheimer's Disease, Brain Diseases, +7 more
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. New Haven, Connecticut, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Washington D.C., District of Columbia, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Indianapolis, Indiana, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. St Louis, Missouri, United States
NCT00481520
- Conditions
- Alzheimer Disease, Brain Diseases, Central Nervous System Diseases, +6 more
- Locations
-
- Delray Beach, Florida, United States
- Hallandale, Florida, United States
- St. Petersburg, Florida, United States
- Atlanta, Georgia, United States
Completed
Pioglitazone in Alzheimer Disease
NCT00982202
- Conditions
- Alzheimer Disease, Brain Diseases, Central Nervous System Diseases, +9 more
- Locations
-
- University Hospitals of Cleveland Cleveland, Ohio, United States
- University of Virginia Charlottesville, Virginia, United States